170 completed, 42 terminated, 29 recruiting, 27 unknown. 294 Phase 2, 58 Phase 1, 22 Phase 3.
Follow Bronchitis: new trials by email Literature Review of Bronchitis trials Research Report on Bronchitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Brenipatide, Placebo, Standard of Care - Pulmonary Disease, Chronic Obstructive | Phase 2 | Recruiting | Eli Lilly and Company | 606 | 2026-08-07 | 2026-11-05 |
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Galvokimig, Placebo - Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | Phase 2 | Recruiting | UCB Biopharma SRL | 402 | 2026-07-27 | 2026-11-06 |
| To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | Expedition Therapeutics, Inc | 600 | 2026-06-30 | 2026-10-28 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| Study of AHB-171 in Chronic Hepatitis B Participants AHB-171 Injection - Hepatitis B, Chronic (CHB) | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 138 | 2026-06-24 | 2026-07-21 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| Brain State-dependent PCMS in Chronic Stroke Brain state-dependent paired corticomotoneuronal stimulation (PCMS) - Stroke | Phase 1 / Phase 2 | Not yet recruiting | University of Texas at Austin | 45 | 2026-01-01 | 2024-12-06 |
| Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression Ketamine hydrochloride, Minimally Enhanced Usual Care, Brief narrative intervention - Chronic Low Back Pain, Depression | Phase 2 | Recruiting | VA Office of Research and Development | 44 | 2025-12-03 | 2025-12-18 |
| A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Sanofi | 37 | 2025-12-02 | 2026-09-22 |
| Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2025-11-07 | 2025-11-10 | |
| A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT Madecassoside Tablets, Standard Therapy - Chronic Graft-Versus-Host Disease, Graft vs Host Disease | Phase 2 | Recruiting | WeiShi | 30 | 2025-09-01 | 2026-05-26 |
| Axatilimab for Sclerotic Chronic Graft-versus-Host Disease Axatilimab, Biospecimen Collection, Questionnaire Administration - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2025-08-06 | 2026-09-24 |
| Chronic Exogenous Ketosis in HFpEF Exogenous Ketone Drink, Placebo - Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction | Phase 2 | Enrolling by invitation | Duke University | 20 | 2025-07-28 | 2026-10-14 |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD Verekitug, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Upstream Bio Inc. | 666 | 2025-07-02 | 2026-07-20 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy Gecacitinib Hydrochloride Tablets - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Recruiting | Yujun DONG | 24 | 2025-06-30 | 2025-06-10 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease Axatilimab, Extracorporeal Photopheresis - Chronic Graft Versus Host Disease, cGVHD | Phase 2 | Recruiting | University of Miami | 49 | 2025-05-05 | 2026-06-22 |
Showing 20 of 294. Sign in to see all of them.
Bronchiolitis Obliterans Syndrome (205) · Pulmonary Disease, Chronic Obstructive (40) · Bronchitis, Chronic (36) · Graft vs Host Disease (27) · Bronchiolitis (26) · Bronchiolitis Obliterans (22) · Emphysema (18) · Leukemia (18) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lung Diseases (8) · Lymphoma, Follicular (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Pain (7) · Hematologic Neoplasms (6)
Respiratory Tract Diseases (292) · Bronchial Diseases (291) · Lung Diseases, Obstructive (290) · Lung Diseases (286) · Bronchiolitis (222) · Immune System Diseases (208) · Organizing Pneumonia (206) · Bronchiolitis Obliterans (200) · Graft vs Host Disease (180) · Pathological Conditions, Signs and Symptoms (115) · Infections (95) · Pathologic Processes (91) · Disease Attributes (79) · Chronic Disease (76)
Rituximab (10) · Prednisone (9) · Sirolimus (9) · belumosudil (9) · ibrutinib (9) · Formoterol Fumarate (8) · axatilimab (7) · montelukast (7) · Azithromycin (6) · Fluticasone (6) · Mycophenolic Acid (6) · Saline Solution (6) · ruxolitinib (6) · Cyclophosphamide (5) · KD025 (5)
AstraZeneca (9) · Novartis Pharmaceuticals (9) · National Cancer Institute (NCI) (8) · Dana-Farber Cancer Institute (7) · Fred Hutchinson Cancer Center (7) · Incyte Corporation (6) · GlaxoSmithKline (5) · M.D. Anderson Cancer Center (5) · Assistance Publique - Hôpitaux de Paris (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · Eli Lilly and Company (3) · Gilead Sciences (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Kadmon, a Sanofi Company (3) · Nanfang Hospital, Southern Medical University (3)
United States (155) · Germany (39) · Canada (36) · United Kingdom (29) · Spain (25) · China (23) · France (20) · Poland (19) · South Korea (19) · Italy (18) · Belgium (15) · Australia (12) · Japan (11) · Russia (11) · Czechia (10)
Stephanie Lee (6) · Esther Garcia, MD (4) · Ahmet Tutuncu, MD, PhD (2) · Aldo T Iacono, MD (2) · Charles S Cox, MD (2) · Christopher G Kanakry, M.D. (2) · Jamie Y Hur, D.O. (2) · John Koreth, MBBS, DPhil (2)
PMID 23861248, PMID 24432712, PMID 25287629, PMID 31260802, PMID 34265047, PMID 34773261, PMID 36440464, PMID 38485149, PMID 39704205, PMID 10387937, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11756187, PMID 11981005, PMID 12070007, PMID 12931119, PMID 14512314, PMID 15142114, PMID 15251978, PMID 15292060, PMID 15613541, PMID 16046530, PMID 16186597, PMID 16239908, PMID 16407509, PMID 16551963, PMID 16788100, PMID 16946302, PMID 17549053, PMID 17671231, PMID 18219306, PMID 18502835, PMID 18827155, PMID 19017883, PMID 19047234, PMID 19439742, PMID 19597425, PMID 19745067, PMID 19750190, PMID 20007923, PMID 20100768, PMID 20399493, PMID 20634158, PMID 20965785, PMID 21039672, PMID 21073773, PMID 21356110, PMID 21471175
2015 (4), P30CA015704 (4), 2009 (3), 2017 (3), 2018 (3), 2014 (2), 2019 (2), 2025 (2), 2005 (1), 2008 (1), 2016 (1), IK2CX002646-01A2 (1), IK2RX003790 (1), P01CA142106 (1), P30CA042014 (1)